Data and Safety Monitoring The Data and Safety Monitoring Committee (DSMC) provides rigorous review of all industry and institutional protocols at the HCCC. More specifically, the primary duties of the DSMC are to: ? prospectively screen all patients entering HCCC investigator-initiated trials for trial-specified eligibility. The study coordinator delivers a completed eligibility checklist, with test results, to the safety officer, who verifies that the inclusion and exclusion criteria are met. Questions or concerns about eligibility are discussed with the DSMC chair and/or the Study Monitor. The safety officer then communicates DSMC approval, questions or concerns to the research team before the subject is enrolled in the trial. ? assess safety by reviewing all severe adverse events and ensure timely and appropriate reporting to oversight agencies (e.g. NCI, FDA, IRB) ? conduct audits of selected trials for data veracity, protocol adherence, and subject safety based on overall HCCC Data and Safety Monitoring Plan and the risk level of the study. The DSMC has the authority to close a clinical trial by contacting the IRB should safety issues warrant such closure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-13
Application #
8466230
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
13
Fiscal Year
2013
Total Cost
$80,424
Indirect Cost
$31,203
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Monga, Varun; Maliske, Seth M; Kaleem, Hassan et al. (2018) Discrepancy between treatment goals documentation by oncologists and their understanding among cancer patients under active treatment with chemotherapy. Eur J Cancer Care (Engl) :e12973
Swami, Umang; Lenert, Petar; Furqan, Muhammad et al. (2018) Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities? J Thorac Oncol 13:e102-e103
Seaman, Aaron T; Dukes, Kimberly; Hoffman, Richard M et al. (2018) The complicated 'Yes': Decision-making processes and receptivity to lung cancer screening among head and neck cancer survivors. Patient Educ Couns 101:1741-1747
Shields, Anthony F; Jacobs, Paula M; Sznol, Mario et al. (2018) Immune Modulation Therapy and Imaging: Workshop Report. J Nucl Med 59:410-417
Vijapura, Charmi; Yang, Limin; Xiong, Jinhu et al. (2018) Imaging Features of Nonmalignant and Malignant Architectural Distortion Detected by Tomosynthesis. AJR Am J Roentgenol 211:1397-1404
Brooks, Nathan A; Boland, Riley S; Strigenz, Michael E et al. (2018) Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years. Urol Oncol 36:501.e9-501.e13
Sandgren, Jeremy A; Deng, Guorui; Linggonegoro, Danny W et al. (2018) Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice. JCI Insight 3:
Jiang, Cheng-Fei; Shi, Zhu-Mei; Li, Dong-Mei et al. (2018) Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. Mol Cancer 17:83
Moss, Jennifer L; Xiao, Qian; Matthews, Charles E (2018) Patterns of cancer-related health behaviors among middle-aged and older adults: Individual- and area-level socioeconomic disparities. Prev Med 115:31-38
Gu, Chunyan; Jing, Xuefang; Holman, Carol et al. (2018) Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer 18:1152

Showing the most recent 10 out of 1080 publications